Company: PHAT
Filing Date: 2025-04-16
Form Type: 8-K
Source: 0001193125-25-082089
Chunk: 0

Company: Phathom Pharmaceuticals, Inc.
Filing Date: 2025-04-16
Form: 8-K
Item: Item 5.02
Chunk 0
---
Item 5.02      Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.  

The board of directors (the “ Board”) of Phathom Pharmaceuticals, Inc. (the “ Company”) appointed Theodore R. Schroeder to the Board as a Class I director, effective April 16, 2025, with an initial term expiring at the 2026 annual meeting of stockholders of the Company. Mr. Schroeder will serve on the audit committee of the Board.

Mr. Schroeder brings more than three decades of experience in drug development and commercialization at both large and small pharmaceutical companies. Mr. Schroeder served as Chief Executive Officer of Nabriva Therapeutics from July 2018 to January 2023 and as a director until March 2025, following Nabriva’s acquisition of Zavante Therapeutics, where he served as co-founder, President, and Chief Executive Officer from June 2015 until July 2018. Mr. Schroeder co-founded Cadence Pharmaceuticals, Inc., a publicly-traded biopharmaceutical company, in May 2004 and served as its President and Chief Executive Officer, and a member of the board of directors, until its acquisition in March 2014 by Mallinckrodt plc, a publicly-traded global biopharmaceutical company. Earlier in his career, he held senior leadership roles at Elan Pharmaceuticals, Dura Pharmaceuticals, and Bristol-Myers Squibb. Mr. Schroeder has served as a director of Cidara Therapeutics, a publicly-traded biopharmaceuticals company, since April 2014 and previously served as a director of several public life sciences companies, including Otonomy, Inc. from August 2015 until January 2023 and Collegium Pharmaceutical from January 2016 until May 2021, as well several other public and private life sciences companies including Hyperion Therapeutics, Incline Therapeutics, and Trius Therapeutics. He is also a former Chairman of Biocom California and the Antimicrobials Working Group. In 2014, he was named EY Entrepreneur of the Year for the San Diego region and was recognized as a national finalist. He holds a B. S. in Management from Rutgers University.

In connection with his appointment to the Board, Mr. Schroeder received an option to purchase 35,000 shares of common stock of the Company and 21,000 restricted stock units